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OVERVIEW OF RESEARCH DESIGN IN
EPIDEMIOLOGY
John Concato, M.D., M.S., M.P.H.*
INTRODUCTION
The objectives of this paper are to first, provide background
regarding a conceptual model of causality in epidemiology;
second, describe common types of structure (architecture) used for
research design in epidemiology, including descriptive, cohort,
case-control, and cross-sectional studies; third, review frequentlyencountered formats for reporting the results of such studies; and
fourth, discuss the strengths and limitations of strategies used in
epidemiology. The first and fourth objectives represent a bigpicture assessment for interpreting epidemiologic studies; whereas
the second and third objectives promote a nuts-and-bolts
understanding of the studies themselves.
I.

CONCEPTUAL MODEL OF CAUSALITY

A discussion of research design involves considerations of the
concept of causality, i.e., what causes disease.1 In this context,
* The author is an Associate Professor of Medicine in the Department of
Internal Medicine at Yale University School of Medicine in New Haven, CT,
and Director of the Clinical Epidemiology Research Center at VA Connecticut
Healthcare System in West Haven, CT. The conclusions and opinions expressed
in this article are those of the author and do not represent any official or
unofficial position of Yale University or the U.S. Department of Veterans
Affairs. Presented at the second Science for Judges Symposium, Brooklyn Law
School, Brooklyn, NY, November 7, 2003.
1
See, e.g., Sir Austin Bradford-A.B. Hill, The Environment and Disease:
Association or Causation?, 58 PROC. R. SOC. MED. 295-300 (1965).
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biological phenomena can be considered either deterministic or
probabilistic. A deterministic situation exists when the exposure
can be linked conclusively to an outcome (e.g., when a particular
genetic rearrangement causes sickle cell anemia). In contrast, a
probabilistic phenomenon occurs when exposure is said to be
associated with an outcome (e.g., if hypertension (high blood
pressure) is associated with stroke). In the first example, the
genetic problem is always found with the disease, and vice versa.
In the second example, hypertension increases the probability of
stroke; but some patients with hypertension do not suffer a stroke,
and some patients with stroke do not have antecedent hypertension.
A major role of epidemiological research design is to provide
information for, or against, a probabilistic association. A
conceptual (intellectual) model2 has been developed for this
purpose, and is often described with terms such as cause-effect
research (Figure 1). The entity being evaluated as a possible cause
of a disease, or other endpoint, is referred to as an exposure, but is
not limited to environmental exposures, and can include a person’s
age, sex, personal habits (such as cigarette smoking), ingested
medications, etc. The entity being assessed as a possible disease or
other endpoint is referred to as an outcome, and can include the
development of a disease, a quality of life measurement, death, etc.
FIGURE 1—CONCEPTUAL MODEL FOR CAUSE-EFFECT RESEARCH
Baseline state → Exposure →
Condition prior
Factor(s) that
to exposure
may lead
or outcome
to outcome
Example:
Healthy adults

→ Hypertension →

Outcome
Disease
or entity
of interest

Stroke

The model can be applied to the association of hypertension
and stroke, addressing the question of whether hypertension can
2

ALVAN R. FEINSTEIN, CLINICAL EPIDEMIOLOGY: THE ARCHITECTURE OF
CLINICAL RESEARCH 50 (Saunders 1985).
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“cause” stroke (in a probabilistic, not a deterministic, sense). In
this example, adults, either with or without hypertension, do or do
not develop subsequent stroke. The challenge involves determining
whether stroke is more common among patients with hypertension;
and if so, whether the corresponding evidence (in the form of data)
is strong enough, and stable enough, to confirm that an association
exists and is “real.”
A useful aspect of cause and effect studies is the ability to
summarize the association of interest with a simplified schematic
(2 × 2 table) showing the relationship of exposure and outcome
(Table 1A). Although most epidemiological investigations involve
more complex designs, the focus of a study can be understood
using this approach. This framework will be used throughout the
subsequent text, with each of the types of research architecture, to
demonstrate basic principles involved.
TABLE 1A—SCHEMATIC OF CAUSE-EFFECT STUDY
Outcome No outcome
Exposure

a

b

No exposure

c

d

Exposure = factor that may “cause” outcome
Outcome = entity (e.g., disease) of interest

II. SPECIFIC TYPES OF RESEARCH DESIGN
Unfortunately, no universally accepted terminology
(classification scheme) exists for types of epidemiologic studies.
Specific terms are often used to describe basic categories and
formats of studies (Figure 2), but the terms may vary with different
authors, leading to potential confusion.3
3

For example, the terms prospective and retrospective are often used to
describe studies, but these terms can be confusing because they are applied to
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FIGURE 2—OVERVIEW OF RESEARCH ARCHITECTURE
Epidemiological Studies

Descriptive studies
• case report/series

“Analytic” studies

Observational studies
• cross-sectional
• observational cohort
• case-control

Experimental studies
• e.g., randomized trial
(experimental cohort)

A. Descriptive Studies
The first category of research design, descriptive studies, has a
limited role in discussions of cause-effect research because such
studies have limited implications regarding (probabilistic)
causation. Descriptive studies are often presented as a case report,
or a case series of patients, and are useful to inform clinical care,
such as a recent report describing severe acute respiratory
syndrome (SARS).4 The strengths and limitations of descriptive
studies in demonstrating causality is illustrated by a descriptive
study reporting on 24 cases of valvular heart disease in patients
taking fenfluramine-phentermine as a dietary suppressant.5 This
article can be considered a prominent, early publication linking
dietary suppressants and valvular heart disease. As noted in the
discussion section of that paper, however, “ . . . definitive
different aspects of study architecture. In addition, I will use the association
between dietary suppressants and heart disease hereafter in the text; I make no
claims about the merit of any related court cases, and I do not imply to present a
comprehensive nor complete assessment of the scientific evidence on this topic.
Finally, I will use the term “patient” frequently, reflecting my training and
experience as a physician; the term person may often be substituted.
4
Nelson Lee et al., A Major Outbreak of Severe Acute Respiratory
Syndrome in Hong Kong, 348 NEW ENG. J. MED., 1986-94 (2003).
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statements about a true association of valvular disease with
fenfluramine-phentermine therapy cannot be made.”5 The
investigation corresponds to the upper left hand “cell” (labeled a)
in Table 1B, indicating that patients with valve defects who had
taken fenfluramine-phentermine were the focus of investigation.
Other descriptive studies may report on patients, for example, in
the top row of cells, but not in all four cells. The importance of this
feature as a limitation of descriptive studies is mentioned in the
discussion of analytic studies.
TABLE 1B—EXAMPLE OF CAUSE-EFFECT STUDY
Valve
defects

No valve
defects

Fen-phen

a

b

No fen-phen

c

d

Fenfluramine-phentermine (fen-phen) is the exposure;
valvular heart disease (valve defect) is the outcome.

B. Analytic Studies
A second, and more commonly encountered, type of study can
be described as analytic (or comparative or cause-and-effect)
studies. This category of study is so common that the term analytic
is not often used; alternatively, terms such as etiologic (what
causes disease), diagnostic (how is disease diagnosed), or
prognostic (what happens to patients with disease), are used to
indicate the main focus of the study, rather than the architecture
itself.
The hallmark of analytic study is that two (or more) groups are
compared to draw an inference regarding a cause-effect
association. Thus, inclusion of a so-called control or comparison
5

Heidi M. Connolly et al., Valvular Heart Disease Associated with
Fenfluramine-Phentermine, 337 NEW ENG. J. MED., 581-88 (1997).
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group is an indication of an analytic study. The presence of the
control group provides a mechanism for establishing whether the
outcome in the exposed group occurs at a higher (vs. lower or
similar) rate, compared with the unexposed group.
Along with opportunity to assess (probabilistic) causation, a
problem called analytic bias can arise in the conduct of analytic
studies. This problem occurs if (various types of) systematic error
exists when assessing the association of interest. For example,
recall bias is considered a problem if certain patients do not recall
accurately their prior exposure. Susceptibility bias is encountered
if compared groups of persons have unequal susceptibility for the
outcome at baseline before considering the impact of a specific
exposure. A general term for these various sources of bias is
confounding; a problem that exists if an extraneous factor
interferes with assessing the relationship between exposure and
outcome, preventing an accurate determination of the true
magnitude of association. A possible example of confounding
involves the question of whether ingestion of dietary suppressants
is associated with heart disease; specifically, whether the
association is confounded by obesity. Obesity is related
(obviously) to ingestion of these products. The problem of
confounding would arise if obesity were also related independently
to valve defects—then dietary suppressants could be a “marker”
for obesity, rather than a causal factor in the development of
valvular heart disease. A solution in this context is to use a
procedure (e.g., adjusting, controlling, matching) that accounts for
confounding variables. These techniques are usually “as good as”
the logic and measurements used in identifying potential
confounding factors; the mathematical procedures, although
complex, are usually not a problem themselves.
1. Observational Studies
Analytic studies are typically described by another feature of
their design; specifically, whether they are observational studies or
experimental studies. Observational studies are investigations in
which exposure is not assigned by a research investigator. Rather,
the exposure occurs via “nature” or as a result of human
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interventions in a non-research setting. For example, exposure to
ambient air pollution would be assessed in an observational study,
as would patients receiving certain medications in the context of
their routine health care. Common examples of observational study
architecture include cross-sectional, observational cohort, and case
control studies.
a. Cross-Sectional Studies
The distinguishing feature of a cross-sectional study is that data
on exposure status and outcome status are obtained at essentially
the same point in time. In an example of a cross-sectional study,
patients were identified from one of three previously conducted
appetite suppressant studies, and new “control” subjects (not in the
appetite studies) were selected based on matching on several
factors (e.g., age, sex, physical features).6 All of the participants
were then assessed for valvular heart disease, and the
corresponding four cells of Table 1B would represent a
simultaneous exposure-outcome relationship. As noted in the
corresponding discussion section of that paper, “the purpose of the
study was to determine the prevalence and severity of valvular
dysfunction in obese patients who had taken appetite suppressants
and those who had not.”6 Although antecedent appetite suppressant
use might result in subsequent valve defects, the study architecture
could not exclude a converse scenario with the onset of heart
disease preceding the ingestion. Thus, the authors were suitably
cautious regarding any claim of causation.
b. Observational Cohort Studies
An observational cohort study differs from a cross-sectional
study in that it involves a longitudinal assessment, usually based
on assembling patients with regard to their status as exposed or not
exposed (Figure 3A). Patients’ exposure status is determined first,
6

Mehmood A. Khan et al., The Prevalence of Cardiac Valvular
Insufficiency Assessed by Transthoracic Echocardiography in Obese Patients
Treated with Appetite-Suppressant Drugs, 339 NEW ENG. J. MED., 713-18
(1998).
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their outcome status is determined subsequently, and then the
association between exposure and outcome is assessed (Table 1B).
A paragraph of an article describing the methods of an example of
an observational cohort analysis stated that the investigators
identified subjects who had been given fenfluramine-phentermine,
and as a comparison group, they identified a group of subjects who
had not received an appetite suppressant.7 The article found that the
risk of valvular disease in subjects who had received certain
dietary suppressants was substantially higher over a five-year
period, indicating the ability of the study to make a claim regarding
causality.8
FIGURE 3A—SCHEMATIC OF COHORT ARCHITECTURE
Longitudinal assessment; start with exposure:

exposed
not exposed

c. Case-Control Studies
A case-control study also involves a longitudinal assessment,
but starts with identifying patients based on their outcome status
(Figure 3B). For example, in a case-control analysis, investigators
compared patients with cardiac-valve abnormalities to patients
without such abnormalities.9 Antecedent ingestion of appetite
suppressants was then determined to establish the association of
interest (Table 1B). The finding that longer use of fenfluramine or
7

H. Jick et al., A Population-Based Study of Appetite-Suppressant Drugs
and the Risk of Cardiac-Valve Regurgitation, 339 NEW ENG. J. MED., 719-24
(1998). Of note, this article included both observational cohort and case-control
analyses within one manuscript; representing an uncommon, but suitable,
format.
8
Id.
9
Id.
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dexfenfluramine was associated with an increased risk of cardiacvalve disorders reflects the analytic nature of the study.
FIGURE 3B—SCHEMATIC OF CASE CONTROL ARCHITECTURE
Longitudinal assessment; start with outcome:
disease

no disease

2. Experimental Studies
The hallmark of an experimental study is that exposure is
assigned by a research investigator. In practical terms, a
randomized controlled trial (or what could be called an
experimental cohort) is the currently accepted experimental design
in clinical research involving intact human beings. The importance
of randomization is that it leads to a balance of risk factors in
exposed and non-exposed groups, promoting an unbiased
evaluation of exposure-outcome associations. An example of a
randomized trial involving dietary supplements is an article that
used data from an earlier randomized, controlled trial comparing
the efficacy and safety of dexfenfluramine and placebo in treating
obesity. 10 Taking advantage of previously collected data (before a
possible link to heart diease was recognized), the authors reported
a “small increase” in the prevalence of valvular disease in patients
10

Neil J. Weissman et al., An Assessment of Heart-Valve Abnormalities in
Obese Patients Taking Dexfenfluramine, Sustained-Release Dexfenfluramine, or
Placebo, 339 NEW ENG. J. MED., 725-32 (1998). It is self-evident that designing
a clinical trial to assess the association between dietary supplements and
valvular heart disease would be unethical.
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treated with fenfluramine.11
3. Other Study Designs
The research designs described in the previous sub-sections
often go by different names, and many other types of research
designs also exist. An example of another type of study is ecologic
analysis, with data for geographic areas (e.g., countries) used in
lieu of individual exposures. Other designs include meta analysis,
in which mathematical pooling of available studies is done,12 and
decision analysis, in which a mathematical model is used to
simulate results for hypothetical patients, based on data from
patient-based studies and other sources.
III. FORMAT FOR REPORTING RESULTS
A discussion of research design would benefit from a
description of the common formats used for reporting their results.
In brief, the results can be thought of as being quantitative
(clinical) and statistical (probabilistic). Quantitative results address
the strength of an association, whereas statistical results address
the stability of an association. As an example of hypothetical
results (Table 2), an association between exposure and disease
among 2,000 patients can be considered.

11

Id.
See John P.A. Ioannidis, M.D. & Joseph Lau, M.D., Systematic Review
of Medica Evidence, 12 J.L. & POL’Y 509 (2004).
12
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TABLE 2—EXAMPLE OF STATISTICAL RESULTS FOR
HYPOTHETICAL STUDY
Disease

No disease

Exposed

60

940

1000

Not exposed

30

970

1000

Relative risk = (60/1000) ÷ (30/1000) = 6% ÷ 3% = 2.0;
95% confidence interval = 1.3 to 3.1; P = 0.001

A. Quantitative Results
A common format for reporting the quantitative strength of the
association is the relative risk (Table 2), representing the rate of
outcome among exposed patients (60/1000 = 6%), divided by the
rate of outcome in the non-exposed group (30/1000 = 3%). The
relative risk is calculated as 2.0 in this situation and would be
stated as “exposed patients were twice as likely to have disease as
non-exposed patients.” A relative risk of 1.0 would indicate no
association (i.e., identical outcome rates for the compared groups),
and is therefore called the null value.
The results for this same hypothetical study can be reported,
however, in many different ways. For example, the relative risk
(just calculated as 2.0) is often replaced by other so-called point
estimates, such as an odds ratio, hazard ratio, rate ratio, or rate per
100 person-years of follow-up (e.g., 10 people for 10 years, or 50
people for two years), depending on the particular research design.
Even if one focuses on a relative risk, however, it should be
appreciated that the comparison of 6% vs. 3% could be described
as an absolute risk difference, calculated as (6% - 3% =) a 3%
increase; or a proportionate difference, calculated as ([6% - 3%] ÷
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3% =) a 100% increase.13 In addition, other formats for reporting
results have been devised, such as the number needed to treat (or in
this situation, the number needed to harm).14
Importantly, no single scientific threshold exists for
quantitative significance, such as determining whether a 6% vs.
3% outcome is big enough. In a legal context, however, a relative
risk of greater than 2 has been cited as representing a situation
where “were the exposures more likely than not the cause”15 of the
outcome. The logic behind this statement is shown in Table 2,
using the same hypothetical study. The explanation is that among
the 60 patients who were exposed and who experienced the
outcome, 30 would have the baseline rate (or expected) outcome,
and 30 more could be attributed to the exposure. Thus, if more than
60 patients are in the upper left hand cell, it is more likely than not
that any given patient’s outcome is due to exposure. From an
epidemiologic perspective, however, this threshold value of 2.0 is
quite arbitrary. The results of any study are subject to statistical
variation as well as bias, such that a relative risk of 2.1 vs. 1.9
would not be considered substantially different by most
epidemiologists.
B. Statistical Results
The same hypothetical study would typically have additional
results reported in Probability (P) values or confidence intervals. In
contrast to quantitative results, threshold values do exist for these
statistical results. Specifically, a P value less than or equal to 0.05,
and a 95% confidence interval that excludes 1.0 (or another null
value) are used to determine that results are “statistically
13

Depending on one’s perspective—especially in a legal setting—one party
might be inclined to report “only” a 3% increase, whereas the other party may
claim a “whopping” 100% increase, for the exact same findings.
14
Ignoring the mathematical calculations involved (1/[0.06 – 0.03] = 1/0.03
= 33.3); the interpretation is that when approximately 33 patients are exposed
(or not) in each arm of the study, one extra outcome would be observed in the
exposed group
15
FED. JUDICIAL CTR., REFERENCE MANUAL ON SCIENTIFIC EVIDENCE 384
(2d ed. 2000).
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significant.”
1. P Values
A P value can be thought of as the probability of an observed
result occurring by chance alone. The P value could range from 0
to 1, where “lower is better,” and P less than or equal to 0.05 is a
threshold value as mentioned previously. If the P value is equal to
0.05, we are acknowledging that there is a 1 in 20 probability of
the result occurring by chance alone, i.e., being a false-positive
result. Using an example from the mathematical concept of
probability, the P value for obtaining 5 consecutive heads when
flipping a fair coin would be (0.5)5= 0.031, or approximately 3 in
100. For 10 consecutive heads, the P value would be (0.5)10 =
0.00098, or less than 1 in 1000. One might “worry” about a coin
having two heads if heads appeared five times in a row, and even
more so for ten times in a row, but either event could happen
potentially. The corresponding interpretation of a study with P =
0.031 would be that the observed result linking exposure to
outcome was unlikely due to chance (less than 0.05); and the
interpretation for a study with P = 0.00098 would be that the
observed result was very unlikely to represent a chance occurrence
(much less than 0.05). The calculated P value for the data in Table
2 is 0.001, indicating a statistically significant (stable) result.
2. Confidence Intervals
The results from Table 2 are illustrated again in Figure 4,
showing the relative risk of 2.0 and a 95% confidence interval
from 1.3 - 3.1; indicating the strength of association may be as low
as 1.3 or as high as 3.1, but the best estimate is 2.0. In this manner,
confidence intervals are shown to express stability of results in
terms of “units” of relative risk (or other point estimates), based on
the same mathematical information as P values. For example, the
observation that the entire 95% confidence interval, including the
lower bound at 1.3, does not overlap the null value of a relative
risk of 1.0, indicates a statistically significant exposure-outcome
association (P < 0.05).
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FIGURE 4—P VALUE AND 95% CONFIDENCE INTERVAL (C.I.)
FOR TABLE 2
Relative risk = 2.0; 95% C.I. = 1.3-3.1; P = 0.001
P < 0.05

relative risk = 1

2

3

decreased risk ← → increased risk
Note that if RR = 1.0, no exposure-outcome
association exists.

The general relationship of P values and confidence intervals is
shown in Figure 5; e.g., if a P value is greater than 0.05 (not
statistically significant), the 95% confidence interval includes the
null value of one.
FIGURE 5—RELATIONSHIP OF P VALUES AND 95% CONFIDENCE
INTERVALS
Relative risk = 1

P < 0.05

P > 0.05
P = 0.05

2

3
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3. Other Considerations
A more in-depth understanding of statistical results can be
aided by evaluating “results” from baseball. When evaluating a
comparison of batting averages, one can consider whether a .333
average is better than a .250 average (Table 3). The answer would
almost certainly be “yes” regarding the quantitative difference, but
most people would agree that results would be unstable (i.e., not
likely to persist) if based, respectively, on 1 hit in 3 at-bats vs. 1 hit
in 4 at-bats, perhaps based on one game at the end of the previous
season. That instability is represented by a calculated P value of
0.81. Importantly, the P value decreases for the same comparison
of batting averages as the denominator (number of at bats)
increases. Thus, by the time these players have 300 and 400 at
bats, respectively, the P value of 0.02 indicates that that difference
is unlikely due to chance. If the batters end up having several
thousand at-bats over the course of their career, the P value shrinks
to a very small number (less than 0.0000001) shown in Table 3;
indicating that the averages are unlikely to be the same, even if the
.333 batter went in to a prolonged slump, and the .250 batter had a
sustained hitting streak. The take-home message is that the larger
the sample size, the smaller the P value, for constant proportions
being compared.
TABLE 3—EXAMPLE OF “LARGE” QUANTITATIVE DIFFERENCE
Player A = .333

Player B = .250

P Value

1/3

1/4

0.81

10/30

10/40

0.45

100/300

100/400

0.02

1000/3000

1000/4000

<0.0000001

Note: The larger the sample size, the smaller the P value,
for constant proportions.
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A second example involving batting averages illustrates the
same issue, with a different perspective (Table 4). In this scenario,
one player has a .288 batting average, where as the second player
has a .282 batting average. The P value of 0.77 indicates that the
two numbers are not statistically significantly different based on
1,000 at bats; and the difference might not have been considered
quantitatively important to start with. Yet, if the number of at-bats
is increased sufficiently, up to (an unrealistic) value of 100,000, a
P value of 0.003 can be obtained. The take-home message here is
that a quantitatively unimportant difference can be statistically
significant (i.e., less than 0.05), with a large enough sample size.
These examples illustrate that a P value and or confidence intervals
can help in evaluating the stability of results, but they do not
themselves address directly the validity or trustworthiness of the
data.
TABLE 4—EXAMPLE OF “SMALL” QUALITATIVE DIFFERENCE
Player A = .288

Player B = .282

P Value

288/1000

282/1000

0.77

2,880/10,000

2,820/10,000

0.35

28,800/100,000

28,200/100,000

0.003

Note: A quantitatively unimportant difference can be made
statistically significant, with a large enough sample size.

IV. STRENGTHS AND LIMITATIONS OF STRATEGIES IN
EPIDEMIOLOGY
An overview of the strategies used in epidemiology can be
discussed in terms of the four stages of analytic study assessing
probabilistic causation: framing a research question; developing a
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study design;16 collecting data; and completing a statistical
analysis.17
A. Framing a Research Question
Issues regarding framing the research question include whether
the topic is relevant and whether the question being posed is
cogent. In medical research, the assessment of importance is often
determined via granting agencies (e.g., the National Institutes of
Health) that provide funding to investigators, or the peer review
process that determines which manuscripts are published in various
medical journals. In legal settings, the adjudication of a
controversy in the courtroom would indicate de facto a substantial
level of importance. Questions and controversies may still arise,
however, regarding, for example, how to interpret studies that
examined similar, but not identical, dietary suppressant drugs, or
studies that did not perform standard diagnostic tests to find
valvular disease among all patients, etc.
B. Developing a Study Design
Randomized controlled trials are less vulnerable to
confounding when compared to observational studies because
randomization balances potential confounding factors with regard
to exposure. In this context, the conventional wisdom for the past
several decades has been that observational studies are always
inferior to randomized trials, due largely to the problem of
confounding. Work done by our group and others,18 however, has
shown that contrary to prevailing beliefs, results from well16

See supra Part II.
See supra Part III.
18
Kjell Benson & Arthur J. Hartz, A Comparison of Observational Studies
and Randomized, Controlled Trials, 342 NEW ENG. J. MED., 1878-86 (2000);
John Concato et al., Randomized, Controlled Trials, Observational Studies, and
the Hierarchy of Research Designs, 342 NEW ENG. J. MED., 1887-92 (2000);
Martin McKee, et al., Methods in Health Services Research: Interpreting the
Evidence: Choosing Between Randomised and Non-Randomised Studies, 319
BRIT. MED. J. 312-5 (1999).
17
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designed observational studies (with a cohort or case-control
design) did not systematically overestimate the magnitude of the
associations between exposure and outcome compared with
randomized, controlled trials. The results suggested that suitable
precautions against bias were taken in higher quality observational
studies, making them comparable to clinical trials in terms of
producing valid results.
This work indicates that epidemiologistsand judgesshould
be flexible in interpreting evidence from various types of study
design. Unfortunately, it is not a simple matter to determine
whether a particular study is valid or not. Various lists (e.g., using
“evidence-based medicine”)19 that attempt to provide a hierarchical
assessment of research design should be viewed with caution.
C. Collecting Data
Data collection is a frequently overlooked activity, often with
assumptions that the activity has been done in a trustworthy
manner. Yet, it is important to note that high quality data are
crucial to ensure the validity of a study, and such data can involve
considerable effort to obtain. For example, large databases often
collect information for one purpose (e.g., health insurance
documentation) and are used for another (medical research), with
incomplete measurements for the factors of interest.20 In contrast, a
review of medical records, or direct examination of patients, might
be more difficult and expensive, but more appropriate. In legal
settings, the collection of data can become an intense focus of
scrutiny, with the motives of investigators called into question.
D. Statistical Analysis
In terms of assuring that a study is done well, statistical
analyses, per se, areperhaps surprisinglynot a critical issue, in
19

Evidence-Based Medicine Working Group, Evidence-Based Medicine: a
New Approach to Teaching the Practice of Medicine, 268 J. AM. MED. ASS’N
2420-25 (1992).
20
See, e.g., John Concato et al., Problems of Comorbidity in Mortality after
Prostatectomy, 267 J. AM. MED. ASS’N 1077-82 (1992).
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most situations. The most difficult aspect of statistical analyses can
be understanding what particular statistical test (procedure) was
used, and why.21 Regardless of the statistical test, however, a point
estimate, and a P value or confidence interval, is usually generated
as a final product of the analysis. Although a particular statistical
approach might obscure the understanding of a study’s results, a
competent biostatistician or other professional with suitable
training should be able to describe the process in “plain English.”
CONCLUSION
Epidemiology is a rigorous and important scientific discipline,
but “truth” is difficult to establish. Specifically, studies differ
regarding characteristics of patients, assessments of exposure and
outcome, possible sources of methodololgical bias, as well as the
potential influence of personal or political views. Contradictory
results from multiple epidemiologic studies should therefore be
resolved by scientific process of reconciling disagreement (e.g.,
evaluating the quality of research methods). This process,
challenging under any circumstances, is made more complex when
legal issues are involved.

21

See John Concato et al., The Risk of Determining Risk with Multivariable
Models, 118 ANNALS INTERNAL MED. 201-10 (1993) (discussing popular
techniques).

